Therapix Biosciences Ltd. (TRPX)’s Financial Results Comparing With BioXcel Therapeutics Inc. (NASDAQ:BTAI)

Therapix Biosciences Ltd. (NASDAQ:TRPX) and BioXcel Therapeutics Inc. (NASDAQ:BTAI) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Therapix Biosciences Ltd. N/A 0.00 7.71M -2.12 0.00
BioXcel Therapeutics Inc. N/A 0.00 19.27M -1.04 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Therapix Biosciences Ltd. and BioXcel Therapeutics Inc.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Therapix Biosciences Ltd. and BioXcel Therapeutics Inc.

Net Margins Return on Equity Return on Assets
Therapix Biosciences Ltd. 0.00% 0% 0%
BioXcel Therapeutics Inc. 0.00% -40.1% -37.6%

Institutional & Insider Ownership

Institutional investors held 0% of Therapix Biosciences Ltd. shares and 20.6% of BioXcel Therapeutics Inc. shares. 2.08% are Therapix Biosciences Ltd.’s share held by insiders. On the other hand, insiders held about 1.1% of BioXcel Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Therapix Biosciences Ltd. 10.12% 25.81% -18.04% 5.64% -14.6% 44%
BioXcel Therapeutics Inc. 8.12% 66.42% 85.45% -0.45% 0% 131.09%

For the past year Therapix Biosciences Ltd. has weaker performance than BioXcel Therapeutics Inc.

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Tel Aviv, Israel.

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is headquartered in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.